Tagged with ALS

Impact of COVID-19 on US Clinical Studies Conducted by Japan-Based Pharmaceutical Companies
Georg Schroeckenfuchs – President MEA and Head Gulf & Saudi Country Group, Novartis
Opportunities for the Life Science Industry in Australia post-COVID
Haitham Habashi – General Manager, Merck KSA
Australia: Growing Clinical Trials Even in Pandemic’s Wake
Susanne Caspar – CEO, Linnea
Georg Boonen – CEO, Max Zeller
Japan PMDA New Drug Approvals 2020
Ans Heirman – AVP Managing Director, MSD Switzerland
Barış Erdoğan – CEO, Clinerion
Filip Standaert – Managing Director Nordics, Johnson & Johnson
Christian Probst – General Manager, GSK Norway
We use cookies to ensure that we give you the best experience on our site. For more info

See our Cookie Privacy Policy Here